Free Trial
NASDAQ:SLS

SELLAS Life Sciences Group Q4 2023 Earnings Report

SELLAS Life Sciences Group logo
$1.92 0.00 (0.00%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$1.93 +0.01 (+0.52%)
As of 07:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SELLAS Life Sciences Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SELLAS Life Sciences Group Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 28, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

SELLAS Life Sciences Group's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

SELLAS Life Sciences Group Earnings Headlines

BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
See More SELLAS Life Sciences Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group (NASDAQ:SLS), a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

View SELLAS Life Sciences Group Profile

More Earnings Resources from MarketBeat